A major challenge in AAV gene therapy has been developing scalable, cost-efficient processes to reliably produce high-quality vectors.

The Assault Amphibious Vehicle is tracking off into the sunset, after over 50 years of delivering Marines to beaches and ...

Asimov has introduced a new manufacturing platform aimed at improving the scalability and consistency of AAV production for gene therapies.

Targovax ASA ( ($GB:0RIS) ) has shared an announcement. Circio Holding ASA announced significant advancements in their AAV-circVec technology, ...

A significant advance in treatment of patients with immunity to AAVs previously ineligible for clinical trials and existing ...

Biogen has discontinued all gene therapy programs using adeno-associated virus (AAV) capsids, instead shifting resources to modalities that have the highest likelihood of achieving better treatment ...

Genethon, a worldwide pioneer and leader in research and development of gene therapy for rare genetic diseases, and Hansa Biopharma, a Sweden-based leader in ...